Here are the 424B prospectus supplements from Immatics N.V. (IMTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IMTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMTX filings page.
Immatics N.V. (IMTX) is conducting a primary offering of 12,945,916 ordinary shares and pre-funded warrants to purchase 4,315,304 ordinary shares at a public offering price of $8.69 per ordinary share and $8.689 per pre-funded warrant. The total public offering price is $149,995,686.50, with an underwriting discount of $9,000,000.11, yielding gross proceeds to Immatics of $140,995,686.39 and estimated net proceeds of about $140.0 million, or $161.1 million if the underwriters exercise their 30‑day option to purchase up to 2,589,184 additional shares.
The company intends to use the net proceeds to fund research and development of its PRAME-focused pipeline, manufacturing and potential commercialization of product candidates, and for working capital and other general corporate purposes. As of June 30, 2026, net tangible book value was $3.32 per share; after this offering (excluding warrant and option exercises) it would be $3.72 per share, implying immediate dilution of about $4.97 per share to new investors.
Immatics N.V., a clinical-stage biotech focused on PRAME-targeted cancer therapies, is conducting a public offering of its ordinary shares listed on Nasdaq as “IMTX.” The company intends to use the net proceeds to fund continued research and development across its PRAME pipeline, support manufacturing and potential commercialization of product candidates, and for working capital and general corporate purposes.
Immatics highlights updated Phase 1a data for its second-generation PRAME cell therapy IMA203CD8, showing a cORR of 36% (23/64), ORR of 46% (32/69) and median duration of response of 9.2 months at a 14‑month median follow-up. In a small ovarian carcinoma subgroup (N=5) at higher dose levels, two patients had confirmed partial responses and one had an unconfirmed partial response. As of September 30, 2025, cash and cash equivalents were €334.9 million and total shareholders’ equity was €416.7 million, providing a substantial capital base ahead of this raise.